Inflammopharmacology

, Volume 16, Issue 3, pp 112–125

Clinical pharmacology of gold

Review

DOI: 10.1007/s10787-007-0021-x

Cite this article as:
Kean, W.F. & Kean, I.R.L. Inflammopharmacol (2008) 16: 112. doi:10.1007/s10787-007-0021-x

Abstract.

Since the dawn of civilization, elemental gold and gold compounds have been revered and utilized by Shamen and medical practitioners alike for many varied pathological problems. In the 20th century following the observations of Jacques Forestier, injectable gold compounds were successfully used for the treatment of rheumatoid arthritis. Of the many compounds developed, gold sodium thiomalate has been the most extensively studied by basic scientists and by clinicians. In the1980s, the oral gold compound auranofin showed promise as a therapeutic contender to injectable gold, but the clinical side effect profile and fear of long term effects of immune suppression by auranofin, resulted in gold sodium thiomalate continuing as the preferred gold compound for rheumatoid treatment. However, the increased use and demonstration of effectiveness of low dose Methotrexate (MTX) in rheumatoid treatment over the last 20 years has resulted in a significant decline in the use of injectable gold sodium thiomalate, this despite the claims and evidence that it remains a useful agent in the management of rheumatoid arthritis. Several authors still contend that the injectable gold compounds can still play a valuable role, and indeed may be the correct first choice in the management of rheumatoid arthritis.

Copyright information

© Springer 2008

Authors and Affiliations

  1. 1.Department of Medicine (Rheumatology)McMaster UniversityHamiltonCanada
  2. 2.Biomedical Research CentreSheffield Hallam UniversitySheffieldUK